Acurx announces positive comparative microbiology and microbiome data for ibezapolstat from phase 2b clinical trial in cdi patients

Ibezapolstat outperformed vancomycin showing eradication of fecal c. difficile at day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin which had eradication of c.

ACXP Ratings Summary

ACXP Quant Ranking